SCHEMBL3196995

SCHEMBL3196995

NS(=O)(=O)NCCc1ccccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
HRH3 Q9Y5N1 1/20 0.56
ALDH1A1 P00352 2/20 0.54
TAAR1 Q96RJ0 1/20 0.54
ALOX15 P16050 1/20 0.54
CYP1A2 P05177 2/20 0.53
RAB9A P51151 1/20 0.52
HRH1 P35367 2/20 0.52
CA1 P00915 3/20 0.51
CA2 P00918 3/20 0.51
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PRMT1 Q99873 1/20 0.48
CA5A P35218 1/20 0.46
CA14 Q9ULX7 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13066644 0.82 L3MBTL1 (0.65) ALDH1A1CA1CA2CA12L3MBTL1
SCHEMBL4616855 0.80 RAB9A (0.67) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL4600923 0.79 LMNA (0.55) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL10967040 0.79 LMNA (0.55) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL4184428 0.77 HRH1 (0.57) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL3220191 0.76 LMNA (0.56) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL8865124 0.76 HRH3 (0.66) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL4616670 0.75 MEN1 (0.56) LMNATDP1HRH3ALDH1A1TAAR1
SCHEMBL1581969 0.75 PKM (0.66) LMNATDP1ALDH1A1RAB9AL3MBTL1
SCHEMBL19392591 0.75 RAB9A (0.69) LMNATDP1HRH3ALDH1A1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 LMNA 1909/4885TDP1 2736/4885HRH3 4643/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 LMNA 2486/4885TDP1 2675/4885HRH3 4767/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 LMNA 1909/4885TDP1 2736/4885HRH3 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.